6:38AM Alexion Pharma beats by $0.09, beats on revs; raises FY11 EPS, rev above consensus (ALXN) 66.06 : Reports Q3 (Sep) earnings of $0.37 per share, excluding non-recurring items, $0.09 better than the Capital IQ Consensus Estimate of $0.28; revenues rose 44.1% year/year to $204 mln vs the $199.2 mln consensus. Co issues upside guidance for FY11, raises EPS to $1.25-1.28, excluding non-recurring items, from $1.15-1.20 vs. $1.18 Capital IQ Consensus Estimate; raises FY11 revs to $770-775 mln from $760-768 mln vs. $767.61 mln Capital IQ Consensus Estimate. The upward revision in revenue guidance reflects continued global growth of Soliris for PNH; no additional contribution is expected from aHUS operations beyond what had been included in earlier forecasts. Guidance for 2011 cost of sales is being reduced from ~13 percent of sales to ~12 percent of sales.
News 
Market Data 
Discover 
